<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974398</url>
  </required_header>
  <id_info>
    <org_study_id>AK105-304</org_study_id>
    <nct_id>NCT04974398</nct_id>
  </id_info>
  <brief_title>A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, multi-center phase III clinical study to compare&#xD;
      the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with&#xD;
      chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS assessed by BIRC based on RECIST v1.1 .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>OS is defined as the time from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is the proportion of subjects with CR or PR based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>From the time of informed consent signed through 90 days after the last dose of penpulimab</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>From first dose of penpulimab through 30 days after last dose of penpulimab</time_frame>
    <description>Serum concentrations of penpulimab in individual subjects at different time points after penpulimab administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA)</measure>
    <time_frame>From first dose of penpulimab through 30 days after last dose of penpulimab</time_frame>
    <description>Number and percentage of subjects with detectable anti-drug antibody (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>Baseline (Tumor tissue samples must be provided to the research center or central laboratory prior to initial administration).</time_frame>
    <description>Detect PD-L1 expression in tumor samples and evaluate the correlation between PD-L1 and efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood EBV level</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Detect the blood EBV level at baseline and changes after administration and evaluate the correlation between EBV and efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A (study group): Penpulimab plus cisplatin and gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B (control group): Placebo plus cisplatin and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penpulimab</intervention_name>
    <description>Group A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle. Afterward, penpulimab will be used for maintenance treatment (200 mg, administered on Day 1 of each cycle, Q3W).</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Group B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle. Afterward, a placebo will be used for maintenance treatment (200 mg, administered on Day 1 of each cycle, Q3W).</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily signed written Informed Consent Form(ICF).&#xD;
&#xD;
          -  Age of ≥ 18 years and ≤ 75 years at the time of enrollment, male or female.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Expected survival of ≥ 3 months.&#xD;
&#xD;
          -  Histologically or cytologically confirmed nasopharyngeal carcinoma.&#xD;
&#xD;
          -  Subjects with primary metastatic (nasopharyngeal carcinoma, stage IVB defined by the&#xD;
             Union for International Cancer Control and the American Joint Committee on Cancer&#xD;
             Staging System edition 8) nasopharyngeal carcinoma who are not suitable for local&#xD;
             treatment or radical treatment; or nasopharyngeal carcinoma subjects who have a&#xD;
             local-regional recurrence and/or distant metastasis more than 6 months after the end&#xD;
             of previous radical treatment (radiotherapy with induction, concurrent, adjuvant&#xD;
             chemotherapy)；No systemic treatment has been received for recurrent or metastatic&#xD;
             nasopharyngeal carcinoma, and local regional recurrence is not suitable for local&#xD;
             treatment or has received local treatment.&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  All female and male subjects of reproductive potential must agree to use an effective&#xD;
             method of contraception, as determined by the Investigator, during and for 150 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with pathologically diagnosed nasopharyngeal adenocarcinoma or sarcoma.&#xD;
&#xD;
          -  Subjects have had another malignancy within 3 years before the first dose, except&#xD;
             nasopharyngeal carcinoma. Subjects with other malignancies that have been cured by&#xD;
             local therapy such as basal or cutaneous squamous cell carcinoma, superficial bladder&#xD;
             cancer, cervix or breast carcinoma in situ are not excluded.&#xD;
&#xD;
          -  Participation in treatment with an investigational drug or use of an investigational&#xD;
             device within 4 weeks before first study dosing.&#xD;
&#xD;
          -  Have previously received immunotherapy, including immune checkpoint inhibitors, immune&#xD;
             checkpoint agonists , immune cell therapy, and other treatments against tumor immune&#xD;
             mechanism.&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within 2 years prior to initial&#xD;
             administration, or as an autoimmune disease that can recur or for which treatment is&#xD;
             planned determined by the investigator.&#xD;
&#xD;
          -  Active or past history of definite inflammatory bowel disease (e.g., Crohn's disease&#xD;
             or ulcerative colitis).&#xD;
&#xD;
          -  History of immunodeficiency; those who test positive for HIV antibody; current chronic&#xD;
             use of systemic corticosteroids or immunosuppressive agents.&#xD;
&#xD;
          -  Known active tuberculosis (TB) (suspected of having active TB need to undergo clinical&#xD;
             examination for exclusion of such possibility); known active syphilis infection.&#xD;
&#xD;
          -  Known history of allotransplantation and allogeneic hematopoietic stem cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Has known active Hepatitis B or Hepatitis C.&#xD;
&#xD;
          -  Active or untreated CNS metastases.&#xD;
&#xD;
          -  Subjects with peripheral neuropathy.&#xD;
&#xD;
          -  Unresolved toxicity from prior anti-tumor therapy, defined as toxicity that has not&#xD;
             recovered .&#xD;
&#xD;
          -  Received a live vaccine within 30 days before the first dose or planned to receive a&#xD;
             live vaccine during the study.&#xD;
&#xD;
          -  Known allergy to any study drug component; known history of serious hypersensitivity&#xD;
             to other monoclonal antibodies.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of The University of Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaosu Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhifang Yao, MD</last_name>
    <phone>+86-0760-89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital and Institute of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical University</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <zip>541001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Cancer Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chaosu Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xiaozhong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

